Literature DB >> 10961808

CD34+ immune suppressive cells in the peripheral blood of patients with head and neck cancer.

R Pandit1, D M Lathers, N M Beal, T Garrity, M R Young.   

Abstract

Patients with head and neck squamous cell carcinoma (HNSCC) have profound defects in their immune defenses. Using immunofluorescent staining and flow cytometric analysis, we found that most patients with HNSCC have increased levels of CD34+ cells within their peripheral blood. These circulating CD34+ cells contribute to the depressed functional competence of the peripheral blood T-lymphocytes. This was demonstrated by the increased level of proliferative responsiveness to interleukin-2 by the patients' peripheral blood T-cells after depletion of CD34+ cells. These results show the importance of CD34+ cells in contributing to the depression of T-lymphocyte function in patients with HNSCC and suggest that strategies designed to reduce the levels of circulating CD34+ cells may enhance the immune reactivity of the patients' circulating T-lymphocytes against the HNSCC.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10961808     DOI: 10.1177/000348940010900809

Source DB:  PubMed          Journal:  Ann Otol Rhinol Laryngol        ISSN: 0003-4894            Impact factor:   1.547


  19 in total

Review 1.  Immunotherapy for head and neck cancer: advances and deficiencies.

Authors:  Anna-Maria De Costa; M Rita I Young
Journal:  Anticancer Drugs       Date:  2011-08       Impact factor: 2.248

Review 2.  Regulation of suppressive function of myeloid-derived suppressor cells by CD4+ T cells.

Authors:  Srinivas Nagaraj; Dmitry I Gabrilovich
Journal:  Semin Cancer Biol       Date:  2012-01-31       Impact factor: 15.707

3.  Use of alpha,25-dihydroxyvitamin D3 treatment to stimulate immune infiltration into head and neck squamous cell carcinoma.

Authors:  Jarrett E Walsh; Anna-Maria Clark; Terry A Day; M Boyd Gillespie; M Rita I Young
Journal:  Hum Immunol       Date:  2010-05-16       Impact factor: 2.850

Review 4.  Role of immature myeloid cells in mechanisms of immune evasion in cancer.

Authors:  Sergei Kusmartsev; Dmitry I Gabrilovich
Journal:  Cancer Immunol Immunother       Date:  2005-07-27       Impact factor: 6.968

5.  All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients.

Authors:  Noweeda Mirza; Mayer Fishman; Ingo Fricke; Mary Dunn; Anthony M Neuger; Timothy J Frost; Richard M Lush; Scott Antonia; Dmitry I Gabrilovich
Journal:  Cancer Res       Date:  2006-09-15       Impact factor: 12.701

Review 6.  Dendritic cell recovery post-lymphodepletion: a potential mechanism for anti-cancer adoptive T cell therapy and vaccination.

Authors:  Mohamed Labib Salem; David J Cole
Journal:  Cancer Immunol Immunother       Date:  2009-11-18       Impact factor: 6.968

7.  Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy.

Authors:  C Marcela Diaz-Montero; Mohamed Labib Salem; Michael I Nishimura; Elizabeth Garrett-Mayer; David J Cole; Alberto J Montero
Journal:  Cancer Immunol Immunother       Date:  2008-04-30       Impact factor: 6.968

8.  1alpha,25-Dihydroxyvitamin D(3) to skew intratumoral levels of immune inhibitory CD34(+) progenitor cells into dendritic cells.

Authors:  Jonathan S Kulbersh; Terry A Day; M Boyd Gillespie; M Rita I Young
Journal:  Otolaryngol Head Neck Surg       Date:  2009-02       Impact factor: 3.497

Review 9.  Myeloid-derived suppressor cells: linking inflammation and cancer.

Authors:  Suzanne Ostrand-Rosenberg; Pratima Sinha
Journal:  J Immunol       Date:  2009-04-15       Impact factor: 5.422

10.  Subsets of myeloid-derived suppressor cells in tumor-bearing mice.

Authors:  Je-In Youn; Srinivas Nagaraj; Michelle Collazo; Dmitry I Gabrilovich
Journal:  J Immunol       Date:  2008-10-15       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.